Ingersoll Rand
Makes compressors, pumps, and precision fluid-handling systems for industrial and life-science processes.
Something off on this page? Send us feedback.
Profile
Manufactures compressors, vacuum systems, blowers, pumps, and precision fluid- and powder-handling equipment for industrial and life-science customers worldwide. Original-equipment sales seed an installed base that generates recurring parts, consumables, repair, and support revenue.
Designs, manufactures, and services compressors, vacuum pumps, blowers, air-treatment systems, power tools, lifting equipment, and fluid-transfer equipment through Industrial Technologies and Services. Precision and Science Technologies supplies pumps, dosing and dispensing systems, gas-management equipment, powder-handling systems, and life-science tools for customers spanning manufacturing, food and beverage, energy, water, and biopharmaceutical markets worldwide.
Combines application engineering, a broad brand portfolio, and a global manufacturing and service footprint to support process-critical equipment where downtime is costly. Acquisitions regularly extend both segments and adjacent technologies. Revenue comes from original equipment and a sizable recurring stream of replacement parts, consumables, repairs, and support; sales flow through direct teams and independent distributors.
Company facts
Key statistics
Year to date −1.5% · Average volume (30d) 4.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 10, 2026 | Morgan Stanley | Target | $80 | $87 | |
| Jul 20, 2026 | Stifel Nicolaus | Target | $90 | $84 | |
| Jun 3, 2026 | Morgan Stanley | Reiterate | Equal Weight | $97 | $80 |
| May 11, 2026 | Evercore ISI | Target | $53 | $84 | |
| Apr 30, 2026 | Robert W. Baird | Target | $115 | $103 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.83 | $0.86 | +4.0% | $1.96B | $2.05B | +4.7% | −1.11% |
| Apr 28, 2026Q1 FY26 | $0.74 | $0.77 | +4.1% | $1.83B | $1.85B | +0.9% | −4.59% |
| Feb 12, 2026Q4 FY25 | $0.91 | $0.96 | +5.8% | $2.04B | $2.09B | +2.3% | +4.57% |
| Oct 30, 2025Q3 FY25 | $0.86 | $0.86 | −0.2% | $1.95B | $1.96B | +0.4% | −3.05% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.72B | $1.89B | $1.96B | $2.09B | $1.85B | $2.05B | |
| Gross profit | $765.5M | $824.9M | $855.2M | $503.2M | $792.4M | $862.6M | |
| Operating income | $302.5M | $76.4M | $375.5M | $663.6M | $289.7M | $380.3M | |
| Net income | $186.5M | −$115.3M | $244.1M | $266.1M | $192.1M | $256.8M | |
| Diluted EPS | $0.46 | −$0.29 | $0.61 | $0.67 | $0.49 | $0.66 | |
| Gross margin | 44.6% | 43.7% | 43.7% | 24.1% | 42.9% | 42.1% | |
| Operating margin | 17.6% | 4.0% | 19.2% | 31.7% | 15.7% | 18.6% |
Fiscal years (4-quarter sums)FY21 $5.15B · FY22 $5.92B · FY23 $6.88B · FY24 $7.24B · FY25 $7.65B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.17B · Total debt $4.83B · Total assets $18.19B · Shareholders' equity $10.18B
Dividends
Raised for 4 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 13, 2026 | Aug 13 | Sep 3 | $0.02 | |
| May 14, 2026 | May 14 | Jun 4 | $0.02 | |
| Mar 4, 2026 | Mar 4 | Mar 26 | $0.02 | |
| Nov 13, 2025 | Nov 13 | Dec 4 | $0.02 | |
| Aug 14, 2025 | Aug 14 | Sep 4 | $0.02 | |
| May 15, 2025 | May 15 | Jun 5 | $0.02 | |
| Mar 5, 2025 | Mar 5 | Mar 27 | $0.02 | |
| Nov 14, 2024 | Nov 14 | Dec 5 | $0.02 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 391.34M · Float 390.52M · 99.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 30.30M | 7.74% | 13F | Aug 7, 2026 |
| Capital World Investors | 27.93M | 7.14% | 13F | Aug 12, 2026 |
| Price T Rowe Associates Inc /MD/ | 27.03M | 6.91% | 13F | Aug 14, 2026 |
| Capital Research Global Investors | 25.22M | 6.44% | 13F | Aug 12, 2026 |
| Vanguard Capital Management LLC | 24.48M | 6.25% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Aurobind Satpathy | director | +11,538 | $86.68 |
| Apr 13, 2026 | Vicente Reynal | director, officer: See Remarks | −30,492 | $88.00 |
| Mar 2, 2026 | Vicente Reynal | director, officer: See Remarks | −118,044 | $94.11 |
| Feb 20, 2026 | Vikram Kini | officer: Senior Vice President and CFO | −28,367 | $96.50 |
| Feb 19, 2026 | John Humphrey | director | −4,300 | $95.90 |
Peers
- Danaher
Dominant in biopharma bioprocessing — Cytiva and Pall directly face ILC Dover.
- IDEX
The only peer named in both IT&S and P&ST sections of IR's 10-K.
- Flowserve
IT&S-named principal competitor — pumps, valves, seals for process industries.
- Dover
P&ST-named — Pumps & Process Solutions spans biopharma and industrial fluids.
- Repligen
Pure-play single-use bioprocess — XCell ATF, TFF filtration, fluid management.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ingersoll Rand | $78.58 | +0.01% | $30.75B | 32.3 | 21.5 | 3.9 | +8.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| IDEX | $230.28 | +0.05% | $16.98B | 33.1 | 25.2 | 4.7 | +6.4% |
| Flowserve | $80.57 | +0.23% | $10.30B | 28.2 | 18.4 | 2.2 | −1.6% |
| Dover | $199.49 | +0.43% | $26.76B | 24.0 | 17.6 | 3.2 | +6.9% |
| Repligen | $181.00 | +2.72% | $9.95B | 241.5 | 78.1 | 12.7 | +11.9% |
| Median | 33.1 | 24.3 | 4.7 | +6.4% |